2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
UK joins Horizon Europe giving access to new research grants
On 7 September, the UK rejoined Horizon Europe, the world’s largest research collaboration programme, with exciting opportunities for research funding and collaboration.
‘Seeing’ the early signs of Parkinson’s
Researchers from University College London and Moorfields Eye Hospital investigated retinal imaging as a potential diagnostic tool for Parkinson’s. The group found changes in the retinas in people with Parkinson’s are detectable years before diagnosis, indicating retinal imaging could be a viable means of identifying disease risk.
The new Multi-arm Multi-stage MAMS trial model for Parkinson’s
One of the most frustrating aspects of the way we currently conduct clinical trials is the long delays between studies. Multi-Arm, Multi-Stage (or MAMS) clinical trials may represent a solution to this cumbersome problem.
Preliminary phase 2 trial results of lixisenatide presented
A one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide has reported positive early results, which indicate that the treatment may slow the progression of motor (or movement) symptoms. Preliminary results of the LixiPark study were presented at the International Parkinson and Movement…
Aspen starts phase 1 stem cell transplant clinical trial
An experimental treatment for Parkinson’s involves the replacement of the lost dopamine neurons by transplanting new cells into the brain. Biotech company Aspen Neuroscience will soon be starting a clinical trial in the US exploring this potential therapy in people with Parkinson’s.